SCHEMBL3063642

SCHEMBL3063642

COc1cscc1C(=O)Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
CTSD P07339 1/20 0.35
HTT P42858 3/20 0.34
GSK3B P49841 1/20 0.34
CYP3A4 P08684 1/20 0.34
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33
HTR1A P08908 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GAA P10253 1/20 0.33
KDM4E B2RXH2 2/20 0.32
NFE2L2 Q16236 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
PTGDR Q13258 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1286669 0.81 HTT (0.48) ALDH1A1HTTCYP3A4MEN1KMT2A
SCHEMBL1432436 0.81 ALDH1A1 (0.48) ALDH1A1HTTLCKFYNKMT2A
SCHEMBL6766241 0.79 KDM4E (0.48) ALDH1A1HTTKMT2AGAAKDM4E
SCHEMBL5010451 0.79 ALDH1A1 (0.41) ALDH1A1HTTCYP3A4MEN1KMT2A
SCHEMBL11505559 0.79 TSHR (0.42) HTTGSK3BCYP3A4KMT2AKDM4E
SCHEMBL10474440 0.79 CTSD (0.56) ALDH1A1CTSDCYP3A4MEN1KMT2A
SCHEMBL3056644 0.75 TSHR (0.39) ALDH1A1GSK3BGAAKDM4ECA12
Bicarbonate SCHEMBL6617803 0.75 CA12 (0.43) ALDH1A1HTTCYP3A4LCKFYN
SCHEMBL13753399 0.73 GAA (0.49) ALDH1A1KMT2AGAAKDM4EHPGD
SCHEMBL8902778 0.73 CYP3A4 (0.54) ALDH1A1HTTCYP3A4LCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023074408-A1 THIOPHENE COMPOUND, METHOD FOR SYNTHESIZING SAME, AND COMPOSITION CONTAINING SAID THIOPHENE COMPOUND 四国化成工業株式会社 2023-05-04 WO disclosed
US-8541406-B2 Thiadiazole derivatives for the treatment of neurodegenerative diseases NV REMYND (BE) 2013-09-24 US disclosed
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2010-10-14 US disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 US disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885CTSD 116/4885HTT 2/4885
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885CTSD 116/4885HTT 2/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885CTSD 116/4885HTT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.